HTL-Strefa S.A.

Manufacture of medical and dental instruments and supplies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2006-05-04
Share capital
2,934,421.10 PLN
Activity description

Htl-Strefa is a global leader in the production of medical devices, specifically safe lancets, personal lancets, injection needles, and reusable lancing devices. Their products are used by medical personnel for capillary blood sampling in diagnostic tests in hospitals, clinics, and laboratories, as well as by diabetics for daily blood sugar monitoring and subcutaneous medication delivery, including insulin. The company has been operating for 25 years.

Registered address
Adamówek 7, 95-035 Ozorków, Poland
Email
Phone
Electronic delivery address
AE:PL-88389-72503-CIRJG-19

Financials

Revenue history (in m)

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 352 days for 2024). All were audited by a statutory auditor.

  • 202515/07/2026
  • 202402/07/2026
  • 202316/07/2024
  • 202215/07/2023
  • 202105/07/2022
  • 202012/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Division · Other manufacturing6 / 493
Top 1.2%
Sector · Manufacturing163 / 11,958
Top 1.4%
City · Ozorków3 / 61
Top 4.9%
Voivodeship · Łódzkie134 / 15,329
Top <1%
Country · Poland3,267 / 297,266
Top 1.1%

Results vs industry

Revenue
This companyUSD 70.70mMedianUSD 287.80kAverageUSD 4.92m
Net profit
This companyUSD -22.59mMedianUSD 10.65kAverageUSD 206.35k
Operating costs
This companyUSD 73.43mMedianUSD 269.05kAverageUSD 4.50m
Assets
This companyUSD 309.03mMedianUSD 221.07kAverageUSD 5.78m

Offer

  • Pen needles
  • Safety pen needles
  • Safety lancets
  • Lancets for lancing devices
  • Lancing devices
Certifications: ISO 13485

Websites

The site is available in: Polish and English.

  • htl-strefa.comStrona główna – High Tech Lab
    WordPressGoogle Tag ManagerYoast SEONginx

Trademarks

The company holds 8 active trademarks registered with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 1998.

MarkNumberClassesStatusProtected until
WE CARE Z.4785069, 10, 16, 41Protected Oct 31, 2027
HAEMOFINE (word)Z.35768810, 16Protected Jul 1, 2029
MediSafe SOLO Z.35202210, 16Protected Feb 13, 2029
Acti-Lance Z.35201810, 16Protected Feb 13, 2029
HTL STREFA (word)Z.28929310, 16Protected Dec 24, 2034
MarkProtected until
WE CARE Oct 31, 2027
HAEMOFINE (word)Jul 1, 2029
MediSafe SOLO Feb 13, 2029
Acti-Lance Feb 13, 2029
HTL STREFA (word)Dec 24, 2034

Job offers

The company has its own careers page: htl-strefa.com/pl/kariera.

Authorized Representatives

Alberto Munzone – Management Board Member
Jakub Gajewski age 40 – Management Board Member
Karolina Zielińska age 42 – Attorney-in-fact (sole)
Stefano Petroni age 55 – President of the Management Board

Manner of representation

Each member of the management board is authorised to represent the company and make declarations on its behalf independently.

Supervisory board

Arrigo Bendi – Supervisory Board Member
Danuta Pajewska age 71 – Supervisory Board Member
Mikołaj Wojciech Pluciński age 53 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2000-07-03.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

27 notices recorded in the Court and Commercial Gazette (MSiG).

Publication dateEvent
Dec 14, 2021Call to creditors
Oct 8, 2018Commercial Companies Code notice
Sep 4, 2017Commercial Companies Code notice
Apr 27, 2017Commercial Companies Code notice
Mar 8, 2017Commercial Companies Code notice

Public aid

12 public aid cases recorded, with a total value of $15,157,711.

PurposeGross amount
Regional investment aid
–
Regional investment aid
–
Regional investment aid
–

European Funds

ProjectEU co-financing
Development of verified and validated prototypes of safe passive needles for subcutaneous and intravenous injections that eliminate the risk of accidental needlestick injuries, together with their production technology.
$1.7M

Regulatory authorisations

AuthorityTypeStatus
Waste generation Active

Competitors

Name
Zarys International sp. z o.o.
Mercator Medical S.A.
Solventum Poland Manufacturing sp. z o.o.
Phillips-Medisize Poland sp. z o.o.
Nemera Szczecin sp. z o.o.
Balton sp. z o.o.
SP Medical sp. z o.o.
Boxmet Medical sp. z o.o.
SUMI sp. z o.o. + limited partnership
Medasept S.A.

Change history

DateEvent
2015-07-03Share capital reduction
2015-05-28Share capital increase
2015-03-19Name change
2015-03-19PKD change
2011-12-16Share capital increase

FAQ

Last updated: 2026-10-06